⌘K
Loading ticker…
Lyell Immunopharma, Inc. Common Stock · Healthcare · Pharmaceutical Products
As of 2026-06-26, Lyell Immunopharma, Inc. Common Stock (LYEL) has a 3-month relative strength percentile of 7 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 39. The current market Stance is 47 (Neutral). Sector: Healthcare. Average daily range 9.6%, relative volume 11.40×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
7 is not yet a leadership-grade RS read, Market Stance is 47
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Daily range, ATR, beta, and the math for a 1-ADR stop.
LYEL is in a stage 3 topping pattern, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -33.2% / -44.1%.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
LYEL is held by 2 ETFs as of Mar 2026. Top owner: VTI at 0.00% weight, $11M notional.
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value |
|---|---|---|
| VTIVanguard Total Stock Market ETF | 0.00% | $11M |
| VXFVanguard Extended Market ETF | 0.00% | $3M |
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LYEL Jan avg: -10.31% median: -6.77% win: 0% σ: 7.87% n: 4 2022-04-12 → 2026-05-29 | LYEL Feb avg: 11.43% median: 10.21% win: 75% σ: 39.22% n: 4 2022-04-12 → 2026-05-29 | LYEL Mar avg: -13.65% median: -20.02% win: 25% σ: 16.01% n: 4 2022-04-12 → 2026-05-29 | LYEL Apr avg: -6.60% median: -3.02% win: 0% σ: 5.76% n: 5 2022-04-12 → 2026-05-29 | LYEL May avg: 9.05% median: -8.10% win: 40% σ: 32.43% n: 5 2022-04-12 → 2026-05-29 | LYEL Jun avg: 2.68% median: 0.45% win: 50% σ: 43.01% n: 4 2022-04-12 → 2026-05-29 (current) | LYEL Jul avg: 5.24% median: 0.96% win: 50% σ: 21.88% n: 4 2022-04-12 → 2026-05-29 | LYEL Aug avg: -3.28% median: -8.06% win: 25% σ: 16.38% n: 4 2022-04-12 → 2026-05-29 | LYEL Sep avg: 3.16% median: 2.29% win: 50% σ: 35.22% n: 4 2022-04-12 → 2026-05-29 | LYEL Oct avg: -8.76% median: -8.60% win: 50% σ: 19.79% n: 4 2022-04-12 → 2026-05-29 | LYEL Nov avg: 4.65% median: 1.47% win: 50% σ: 29.91% n: 4 2022-04-12 → 2026-05-29 | LYEL Dec avg: -2.37% median: -2.72% win: 50% σ: 27.53% n: 4 2022-04-12 → 2026-05-29 |